比较一线化疗后人表皮生长因子受体1/2阳性转移性膀胱癌患者接受拉帕替尼维持治疗与安慰剂的III期双盲随机试验
该III期双盲随机试验在446例转移性尿路上皮膀胱癌患者中筛选HER1/HER2过表达者,232例HER1或HER2阳性且在化疗后未进展的患者随机接受拉帕替尼或安慰剂维持治疗。拉帕替尼组与安慰剂组的中位无进展生存期分别为4.5个月和5.1个月(HR 1.07,95%CI 0.81-1.43,P=0.63),总生存期分别为12.6个月和12.0个月(HR 0.96,95%CI 0.70-1.31,P=0.80),均无显著差异。结论:在标准治疗基础上加用拉帕替尼维持治疗未显著改善结局。
要点
- 拉帕替尼组与安慰剂组的中位PFS分别为4.5和5.1个月(HR 1.07,P=0.63)。
- 拉帕替尼组与安慰剂组的中位OS分别为12.6和12.0个月(HR 0.96,P=0.80)。
- HER1/HER2强阳性、仅HER1阳性、仅HER2阳性亚组均未见显著获益(P均>0.05)。
核心结论
- 在标准治疗基础上加用拉帕替尼维持治疗未显著改善HER1/HER2阳性转移性尿路上皮膀胱癌患者的结局。
研究设计与样本
- III期双盲随机对照试验,2007年至2013年筛查446例转移性尿路上皮膀胱癌患者,232例HER1或HER2阳性且一线化疗后未进展者按1:1随机接受拉帕替尼或安慰剂维持治疗。
主要发现
- 拉帕替尼组与安慰剂组的中位PFS分别为4.5个月(95%CI 2.8-5.4)和5.1个月(95%CI 3.0-5.8),HR 1.07(95%CI 0.81-1.43),P=0.63。
- 拉帕替尼组与安慰剂组的中位OS分别为12.6个月(95%CI 9.0-16.2)和12.0个月(95%CI 10.5-14.9),HR 0.96(95%CI 0.70-1.31),P=0.80。
- 因不良事件停药率拉帕替尼组为6%,安慰剂组为5%;3-4级不良事件发生率拉帕替尼组为8.6%,安慰剂组为8.1%(P=0.82)。
- 预设亚组分析显示,HER1/HER2强阳性(免疫组化3+,n=111)、仅HER1阳性(n=102)和仅HER2阳性(n=42)患者中拉帕替尼在PFS和OS方面均无显著获益(各P>0.05)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Purpose To establish whether maintenance lapatinib after first-line chemotherapy is beneficial in human epidermal growth factor receptor (HER) 1/HER2-positive metastatic urothelial bladder cancer (UBC). Methods Patients with metastatic UBC were screened centrally for HER1/HER2 overexpression. Patients who screened positive for HER1/2 and who did not have progressive disease during chemotherapy (four to eight cycles) were randomly assigned one to one to lapatinib or placebo after completion of first-line/initial chemotherapy for metastatic disease. The primary end point was progression-free survival (PFS). Results Between 2007 and 2013, 446 patients with UBC were screened, and 232 with HER1- or HER2-positive disease were randomly assigned. The median PFS for lapatinib and placebo was 4.5 (95% CI, 2.8 to 5.4) and 5.1 (95% CI, 3.0 to 5.8) months, respectively (hazard ratio, 1.07; 95% CI, 0.81 to 1.43; P = .63). The overall survival for lapatinib and placebo was 12.6 (95% CI, 9.0 to 16.2) and 12.0 (95% CI, 10.5 to 14.9) months, respectively (hazard ratio, 0.96; 95% CI, 0.70 to 1.31; P = .80). Discontinuation due to adverse events were similar in both arms (6% lapatinib and 5% placebo). The rate of grade 3 to 4 adverse events for lapatinib and placebo was 8.6% versus 8.1% ( P = .82). Preplanned subset analysis of patients strongly positive for HER1/HER2 (3+ on immunohistochemistry; n = 111), patients positive for only HER1 (n = 102), and patients positive for only HER2 (n = 42) showed no significant benefit with lapatinib in terms of PFS and overall survival ( P > .05 for each). Conclusion This trial did not find significant improvements in outcome by the addition of maintenance lapatinib to standard of care.
引用
- Powles T, Huddart RA, Elliott T, et al. Phase III, Double-Blind, Randomized Trial That Compared Maintenance Lapatinib Versus Placebo After First-Line Chemotherapy in Patients With Human Epidermal Growth Factor Receptor 1/2-Positive Metastatic Bladder Cancer. J Clin Oncol. 2016. PMID: 28034079
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。